Elin V Johansson Boll1, Linda M N K Ekström1, Christophe M Courtin2, Jan A Delcour2, Anne C Nilsson1, Inger M E Björck1, Elin M Östman3. 1. Food for Health Science Centre, Lund University, Lund, Sweden. 2. Laboratory of Food Chemistry and Biochemistry and Leuven Food Science and Nutrition Research Centre (LFORCE), Department of Microbial and Molecular Systems (M2S), KU Leuven, Leuven, Belgium. 3. Food for Health Science Centre, Lund University, Lund, Sweden. Elin.Ostman@food-health-science.lu.se.
Abstract
PURPOSE: Specific combinations of dietary fiber (DF) have been observed to result in improved glucose tolerance at a subsequent standardized breakfast. Arabinoxylan oligosaccharides (AXOS) are considered as DF with prebiotic potential, but so far no studies have investigated their metabolic effects in humans. This randomized cross-over study evaluated the overnight impact of breads containing AXOS-rich wheat bran extract and resistant starch (RS, Hi-Maize), separately or combined, on glucose tolerance, related metabolic parameters and markers of gut fermentation in healthy subjects. METHODS: Evening reference and test products were: (1) reference white wheat flour bread (WWB), WWB supplemented with (2) AXOS and RS (WWB + AXOS + RS), (3) an increased content of either AXOS (WWB + hiAXOS) or (4) RS (WWB + hiRS). At the subsequent standardized breakfast, blood was sampled for 3 h to monitor glucose, insulin, nonesterified fatty acids, glucagon-like peptide (GLP)-1 and GLP-2. Breath hydrogen (H2) and short chain fatty acids (SCFA) were measured as markers of gut fermentation, and subjective appetite was rated using visual analog scales. RESULTS: Dose-dependent decreases in glucose responses were observed with increased AXOS over the duration of 3 h. Insulin sensitivity index was improved in the morning after the WWB + hiAXOS evening meal. An increase in breath H2 concentration and circulating SCFA was observed in the morning after both evening meals containing AXOS. CONCLUSION: The present study indicates that AXOS have the potential of improving glucose tolerance in an overnight perspective and suggested mechanisms are improved insulin sensitivity and increased gut fermentation.
RCT Entities:
PURPOSE: Specific combinations of dietary fiber (DF) have been observed to result in improved glucose tolerance at a subsequent standardized breakfast. Arabinoxylan oligosaccharides (AXOS) are considered as DF with prebiotic potential, but so far no studies have investigated their metabolic effects in humans. This randomized cross-over study evaluated the overnight impact of breads containing AXOS-rich wheat bran extract and resistant starch (RS, Hi-Maize), separately or combined, on glucose tolerance, related metabolic parameters and markers of gut fermentation in healthy subjects. METHODS: Evening reference and test products were: (1) reference white wheat flour bread (WWB), WWB supplemented with (2) AXOS and RS (WWB + AXOS + RS), (3) an increased content of either AXOS (WWB + hiAXOS) or (4) RS (WWB + hiRS). At the subsequent standardized breakfast, blood was sampled for 3 h to monitor glucose, insulin, nonesterified fatty acids, glucagon-like peptide (GLP)-1 and GLP-2. Breath hydrogen (H2) and short chain fatty acids (SCFA) were measured as markers of gut fermentation, and subjective appetite was rated using visual analog scales. RESULTS: Dose-dependent decreases in glucose responses were observed with increased AXOS over the duration of 3 h. Insulin sensitivity index was improved in the morning after the WWB + hiAXOS evening meal. An increase in breath H2 concentration and circulating SCFA was observed in the morning after both evening meals containing AXOS. CONCLUSION: The present study indicates that AXOS have the potential of improving glucose tolerance in an overnight perspective and suggested mechanisms are improved insulin sensitivity and increased gut fermentation.
Authors: Liza A H Rosén; Lorena O Blanco Silva; Ulrika K Andersson; Cecilia Holm; Elin M Ostman; Inger M E Björck Journal: Nutr J Date: 2009-09-25 Impact factor: 3.271
Authors: A M Neyrinck; V F Van Hée; N Piront; F De Backer; O Toussaint; P D Cani; N M Delzenne Journal: Nutr Diabetes Date: 2012-01-23 Impact factor: 5.097
Authors: Mattea Müller; Gerben D A Hermes; Canfora Emanuel E; Jens J Holst; Erwin G Zoetendal; Hauke Smidt; Freddy Troost; Frank G Schaap; Steven Olde Damink; Johan W E Jocken; Kaatje Lenaerts; Ad A M Masclee; Ellen E Blaak Journal: Gut Microbes Date: 2020-01-25
Authors: Inmaculada López-Almela; Marina Romaní-Pérez; Clara Bullich-Vilarrubias; Alfonso Benítez-Páez; Eva M Gómez Del Pulgar; Rubén Francés; Gerhard Liebisch; Yolanda Sanz Journal: Gut Microbes Date: 2021 Jan-Dec
Authors: Michelle J Alfa; David Strang; Paramjit S Tappia; Nancy Olson; Pat DeGagne; David Bray; Brenda-Lee Murray; Brett Hiebert Journal: Front Med (Lausanne) Date: 2018-01-22
Authors: Manuel A González Hernández; Ellen E Blaak; Nicole T H Hoebers; Yvonne P G Essers; Emanuel E Canfora; Johan W E Jocken Journal: Front Endocrinol (Lausanne) Date: 2021-06-17 Impact factor: 5.555